Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.89)
# 291
Out of 4,455 analysts
89
Total ratings
68%
Success rate
57.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Maintained: Buy | $82 | $71.96 | +13.95% | 8 | Jun 23, 2026 | |
| NUVL Nuvalent | Downgraded: Hold | $128 → $124 | $123.52 | +0.39% | 10 | Jun 9, 2026 | |
| LONA LeonaBio | Initiated Coverage: Buy | $20 | $9.40 | +112.77% | 1 | May 27, 2026 | |
| TARA Protara Therapeutics | Maintained: Buy | $24 | $4.12 | +482.52% | 7 | May 20, 2026 | |
| TNGX Tango Therapeutics | Downgraded: Hold | $14 → $24 | $31.47 | -23.74% | 4 | May 15, 2026 | |
| RLMD Relmada Therapeutics | Maintained: Buy | $12 | $6.69 | +79.37% | 2 | May 13, 2026 | |
| ERAS Erasca | Maintained: Buy | $18 | $16.01 | +12.43% | 5 | May 12, 2026 | |
| JANX Janux Therapeutics | Maintained: Buy | $30 → $26 | $14.94 | +74.03% | 7 | May 8, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $120 → $172 | $182.08 | -5.54% | 8 | May 7, 2026 | |
| ORIC ORIC Pharmaceuticals | Maintained: Buy | $22 | $9.53 | +130.85% | 5 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $17 → $16 | $14.01 | +14.20% | 4 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $34.54 | +15.81% | 8 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $11.39 | +251.19% | 3 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1.75 | - | 1 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $1.71 | +367.84% | 4 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 | $26.87 | +33.98% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $2.32 | n/a | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.87 | n/a | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $4.25 | n/a | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.81 | n/a | 1 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $28.69 | n/a | 1 | Oct 31, 2022 |
CG Oncology
Jun 23, 2026
Maintained: Buy
Price Target: $82
Current: $71.96
Upside: +13.95%
Nuvalent
Jun 9, 2026
Downgraded: Hold
Price Target: $128 → $124
Current: $123.52
Upside: +0.39%
LeonaBio
May 27, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $9.40
Upside: +112.77%
Protara Therapeutics
May 20, 2026
Maintained: Buy
Price Target: $24
Current: $4.12
Upside: +482.52%
Tango Therapeutics
May 15, 2026
Downgraded: Hold
Price Target: $14 → $24
Current: $31.47
Upside: -23.74%
Relmada Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $12
Current: $6.69
Upside: +79.37%
Erasca
May 12, 2026
Maintained: Buy
Price Target: $18
Current: $16.01
Upside: +12.43%
Janux Therapeutics
May 8, 2026
Maintained: Buy
Price Target: $30 → $26
Current: $14.94
Upside: +74.03%
Revolution Medicines
May 7, 2026
Maintained: Buy
Price Target: $120 → $172
Current: $182.08
Upside: -5.54%
ORIC Pharmaceuticals
May 5, 2026
Maintained: Buy
Price Target: $22
Current: $9.53
Upside: +130.85%
May 1, 2026
Maintained: Hold
Price Target: $17 → $16
Current: $14.01
Upside: +14.20%
Apr 20, 2026
Maintained: Buy
Price Target: $40
Current: $34.54
Upside: +15.81%
Apr 20, 2026
Maintained: Buy
Price Target: $40
Current: $11.39
Upside: +251.19%
Mar 26, 2026
Maintained: Buy
Price Target: n/a
Current: $1.75
Upside: -
Mar 17, 2026
Maintained: Buy
Price Target: $8
Current: $1.71
Upside: +367.84%
Dec 8, 2025
Maintained: Buy
Price Target: $36
Current: $26.87
Upside: +33.98%
May 15, 2025
Reiterated: Buy
Price Target: $5
Current: $2.32
Upside: n/a
May 7, 2025
Reiterated: Buy
Price Target: $8
Current: $2.87
Upside: n/a
Apr 1, 2025
Maintained: Hold
Price Target: n/a
Current: $4.25
Upside: n/a
Jul 30, 2024
Downgraded: Hold
Price Target: n/a
Current: $4.81
Upside: n/a
Oct 31, 2022
Initiated Coverage: Hold
Price Target: n/a
Current: $28.69
Upside: n/a